TABLE 1.
Patient | No. of days after transplantation (viremia episode) | Cumulative no. of days of GCV treatment (route) | Antiviral regimen at time of sampling (route) | Viral load in PMNL by:
|
UL97 mutation detectedc | |
---|---|---|---|---|---|---|
pp65 antigenemia assaya | PCRb | |||||
1 | 98 (first) | 14 (i.v.), 35 (p.o.d) | GCV (p.o.) | 0 | 1.63 × 103 | None |
2 | 63 (first) | 14 (i.v.) | GCV (i.v.) | 0 | 1.13 × 103 | None |
3 | 91 (second) | 14 (i.v.), 14 (p.o.) | None | 8 | 1.17 × 104 | None |
4 | 77 (second) | 14 (i.v.), 14 (p.o.) | None | 1 | 2.51 × 102 | None |
5 | 84 (first) | 14 (i.v.), 12 (p.o.) | GCV (p.o.) | 0 | 2.90 × 103 | None |
6 | 84 (second) | 14 (i.v.), 14 (p.o.) | None | 0 | 8.56 × 102 | None |
7 | 77 (first) | 14 (i.v.), 7 (p.o.) | GCV (p.o.) | 0 | 8.31 × 102 | None |
8 | 77 (second) | 28 (i.v.), 14 (p.o.) | None | 18 | 1.65 × 104 | None |
91 (second) | 42 (i.v.), 14 (p.o.) | GCV (i.v.) | 0 | 8.80 × 102 | None | |
9 | 70 (second) | 14 (i.v.), 14 (p.o.) | None | 1 | 1.88 × 104 | S510 |
77 (second) | 21 (i.v.), 14 (p.o.) | GCV (i.v.) | 2 | 5.64 × 104 | S510 | |
10 | 70 (first) | 14 (i.v.), 14 (p.o.) | GCV (p.o.) | 0 | 4.59 × 102 | None |
84 (second) | 14 (i.v.), 14 (p.o.) | None | 4 | 1.72 × 104 | None |
CMV pp65 antigenemia assay results are expressed as the numbers of positive cells per 2 × 105 PMNL.
COBAS AMPLICOR CMV MONITOR test (PCR) results are expressed as the numbers of CMV copies per 4 × 106 PMNL.
A rapid screening assay detected UL97 mutations Q520, S595, and F595 as well as other mutations at codons 460 and 594. The S510 mutation has a restriction pattern similar to that of a Q520 mutation.
p.o., per os.